Year-over-year earnings per share growth for the last twelve months: Intensity Therapeutics (INTS)
Intensity Therapeutics generates revenue through the sale of innovative agents for intratumoral targeting of metastases. The company's environmental responsibility is reflected in the modernization of laboratory filtration and energy conservation. Quarterly EPS fluctuations clearly confirm the current trend, where the 29.60 mark records this metric. However, intensive expenditures on the final stages of clinical trials create significant financial pressure and a dependence on external capital.
Comprehensive metric breakdowns and analytics for Intensity Therapeutics (INTS)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- book capitalization data:
- debt and liquidity details:
Debt to Equity Intensity Therapeutics|INTS - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity intensitytherapeutics.com|INTS - Company Cumulative Debt|Debt to Book Value Intensity Tx|INTS - Long-Term Indebtedness|Company Current Liabilities Intensity Therapeutics|Quick Ratio intensitytherapeutics.com
- earnings and market multiples details:
INTS - Final Profit|Projected Future Earnings Intensity Therapeutics|INTS - Market Cap to Earnings|Future Price to Earnings intensitytherapeutics.com|INTS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Intensity Tx|INTS - Operating profit EBITDA|Earnings per share for the last twelve months Intensity Therapeutics|INTS - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months intensitytherapeutics.com|INTS - Earnings per share growth rate in current year|Earnings growth forecast for next year Intensity Therapeutics
Comprehensive company analysis:Intensity Therapeutics Inc, INTS
This indicator measures the percentage change in quarterly net earnings per share, reflecting the efficiency of business capitalization and the pace of value generation. Analyzing the quarterly earnings per share trend allows for the timely detection of fading growth momentum, which is critical for Intensity Therapeutics (INTS) while awaiting clinical trial results for INT230-6 or payments from partners.
Competitors of Intensity Therapeutics
IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Janux Pharma|Year-over-year net earnings per share growth for the last 12 months Arcus Corp (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc. (ZYME)|Year-over-year net earnings per share growth for the last 12 months tangotx.com TNGX|Iovance Biotherapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics NV IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (Compass Therapeutics Corp) - Year-over-year earnings per share growth for the last 12 months|Replimune Group, Inc. (REPL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months lyell.com (LYEL)|Year-over-year net earnings per share growth for the last 12 months IPHA|PYXS - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months CGEN (Compugen Ltd.)|Year-over-year earnings per share growth rate for the last twelve months IOBT|Quarterly EPS earnings growth STRO (Sutro Biopharma, Inc.)|Year-over-year earnings per one share growth for the last 12 months INKT|Werewolf - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immix Biopharma, Inc.|ALX Oncology (ALXO) - Year-over-year earnings per share growth for the last twelve months|Cue Biopharma Inc. - Year-over-year earnings per one share growth for the last 12 months|PDSB (PDS Biotech) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Sonnet BioTherapeutics Holdings Inc.|Year-over-year earnings per share growth for the last twelve months MAIA Biotechnology, Inc. (MAIA)|LIMN: Year-over-year net earnings per share trend for the last twelve months|LAVA Therapeutics - Year-over-year net earnings per share growth for the last 12 months|NextCure Corporation (NXTC) - Earnings per share growth in annualized terms for the last twelve months|Leap Tx - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Sensei Biotherapeutics SNSE|Theriva Biologics (TOVX) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months GRTS|Year-over-year net earnings per share growth for the last 12 months KA|NEXI (NexImmune Corporation) - Year-over-year earnings per share growth rate for the last twelve months|Quarterly EPS earnings growth TSBX|VCNX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Harpoon Therapeutics, Inc. HARP
